DYSLIPIDEMIAS AND THEIR ASSOCIATION WITH CHRONIC NON-INFECTIOUS DISEASES (MERIDIAN-RO STUDY)

Objective: to study the frequency of lipid disorders and their association with chronic non-communicable diseases (NCD) in the unorganized population of Ryazan’ region 25–64 yo.

Materials and methods. The study was conducted as a prospective cohort with a cross-sectional retrospective and included the study of biochemical samples, an electrocardiogram and a survey using a standardized questionnaire. In a study in 1622 people were included in 2011 (1220 – city, 402 – rural) in the 25–64 years of age (mean age – 43.4 ± 11.4 years), of which, 42.6 % were male, 53.8 % – female. The cohort was observed 36 months, annually evaluated endpoints. Dyslipidemia was considered as total cholesterol greater than 5 mmol/L and/or low density lipoprotein more than 2.5 mmol/L.

Results. The prevalence of dyslipidemia in the population of the Ryazan region was 84.1 % (81.4 % – the city, 89.3 % – the village, p = 0.0001). It was found that an increase in apolipoprotein B, more than 180 mg/dL was associated with an increased risk of more than 5 % on the SCORE (OR 1.81, 95 % CI 1.61–2.03), diabetes (OR 1.87, 95 % CI 1,38–2,54), hypertension (OR 1.44, 95 % CI 1.29–1.60), CKD (OR 1.83, 95 % CI 1.28–2.62), gastrointestinal diseases (OR 1.12, 95 % CI 1.02–1.24), and ischemic heart disease/stroke/myocardial infarction combined point (ОR 1.61, 95 % CI 1.05–2.46). Increased total cholesterol greater than 5 mmol/L or low-density lipoprotein cholesterol greater than 2.5 mmol/L was also associated with hypertension (OR 1.28, 95 % CI 1.08–1.51), CKD (OR 1.97, 95 % CI 1.04–3.71) and dorsopathy. Links with ischemic heart disease/stroke/myocardial infarction has been received (ОR 0.89, 95 % CI 0.51– 1.56). Ups increased the risk of death from all causes (RR 3.98, 95 % CI 1.48–10.70, p = 0.006) and the combined endpoint (RR 7.12, 95 % CI 3.26–15.57, p = 0.0001).

Conclusion. The frequency of dyslipidemia in the Ryazan’ region was high and amounted to 84.1 %. Adverse outcomes of NCD associated with elevated levels of apoB in the MERIDIAN-RO study, which should be considered when assessing the atherogenic dyslipidemia.

1. Quehenberger O., Dennis E.A. The human plasma lipidome. N Engl J Med 2011;365(19):1812–23.

2. Lipid metabolites and pathways strategies (LIPID MAPS). Lipidomics gateway national institute of general medical sciences. Доступно по ссылке: http://lipidmaps.org; дата последнего обновления: 31/07/15 г.

3. Оганов Р.Г., Шальнова С.А., Калинина А.М. Профилактика сердечно-сосудистых заболеваний: руководство. М.: ГЭОТАР-Медиа, 2009. [Оganov R.G., Shal’nova S.А., Kalininа А.М. Prophylactics of cardiovascular diseases. Мoscow: GEOTAR-Меdiа, 2009. (In Russ.)].

4. Кардиология: национальное руководство. Под ред. Е.В. Шляхто. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015. [Cardiology: national guidelines. Ed. by Е.В. Shlyakhto. 2nd revised edn. Мoscow: GEOTAR-Меdiа, 2015. (In Russ.)].

5. Prospective Studies Collaboration, Lewington S., Whitlock G., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007;370(9602):1829–39.

6. Verschuren W.M., Jacobs D.R., Bloemberg B.P. et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-fiveyear follow-up of the seven countries study. JAMA 1995;274(2):131–6.

7. Chen Z., Peto R., Collins R. et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303(6797):276–82.

8. Ford E.S., Mokdad A.H., Giles W.H., Mensah G.A. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003;107(17):2185–9.

9. Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937–52.

10. Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37(29):2315–81.

11. Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2014;13(6):4–11. [Мuromtsevа G.А., Kontsevaya А.V., Konstantinov V.V. et al. Prevalence of infectious diseases’ risk factors in the Russian population in 2012–2013. Results of ESS-RF studies. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prophylactics 2014;13(6):4–11. (In Russ.)].

12. Метельская В.А., Шальнова С.А., Деев А.Д. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина 2016;19(1):15–23. [Меtel’skaya V.А., Shal’novа S.А., Deev А.D. et al. Аnalysis of prevalence of indices, characterizing the aterogeneity of the spectrum of licoproteins at residents of the Russian Federation (by the data of the ESSE-RF studies). Profilakticheskaya meditsina = Prophylactic Medicine 2016;19(1):15–23. (In Russ.)].

13. Якушин С.С., Шальнова С.А., Потемкина Р.А. и др. Опыт организации эпидемиологического исследования факторов риска неинфекционных заболеваний в Рязанской области (по результатам пилотного проекта МЕРИДИАН-РО. Профилактическая медицина 2012:15(6):20–4. [Yakushin S.S., Shal’novа S.А., Potemkinа R.А. et al. Experience of the organization of the epidemiologic study of non-infectious diseases’ risks’ factors in Ryazan region (by results of MERIDIAN-RO pilot project. Profilakticheskaya meditsina = Prophylactic Medicine 2012:15(6):20–4. (In Russ.)].

14. Бритов А.Н., Поздняков Ю.М., Волкова Э.Г. и др. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика 2011;10(6 Прил. 2):2–64. [Britov А.N., Pozdnyakov Yu.М., Volkovа E.G. et al. National recommendations for cardiovascular prophylactics. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prophylactics 2011;10(6 Suppl. 2):2–64. (In Russ.)].

15. Conroy R.M., Pyörälä K., Fitzgerald A.P. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24(11):987–1003.

16. Ahmad O.B., Boschi-Pinto C., Lopez A.D. et al. Age standardization of rates: a new who standard. GPE Discussion Paper Series: No 31, EIP/GPE/EBD World Health Organization, 2001. Рp. 1–14.

17. Распределение численности населения по полу и возрасту на 1 января 2012 года. Доступно по ссылке: http://ryazan.gks.ru. [Prevalence of the population by sex and age by January 1 2012. Available at: http://ryazan.gks.ru. (In Russ.)].

18. Bonow R.O., Mann D.L., Zipes D.P. et al. Braunwald’s heart disease: a textbook of cardiovascular medicine: 9th edn. Elsevier, 2015.

19. Бойцов С.А. Структура факторов сердечно-сосудистого риска и качество мер их профилактики в первичном звене здравоохранения в России и в Европейских странах (по результатам исследования EURIKA). Кардиоваскулярная терапия и профилактика 2012;11(1):11–6. [Boytsov S.А. Structure of factors of the cardiovascular risk and the quality of measures for its prophylactics in the primary healthcare chain in Russia and European countries (by results of EURIKA studies). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prophylactics 2012;11(1):11–6. (In Russ.)].

20. Ооржак Н.С., Каскаева Д.С., Петрова М.М. и др. Особенности факторов риска артериальной гипертонии в организованной популяции мужчин города Кызыла. Сибирское медицинское обозрение 2012;75(3):45–8. [Ооrzhak N.S., Kaskaevа D.S., Petrovа М.М. et al. Peculiarities of the arterial hypertension risk factors in the organized population of men of the town of Kyzyl. Sibirskoe meditsinskoe obozrenie = Siberian Medical Review 2012;75(3):45–8. (In Russ.)].

21. Штарик С.Ю. Распространенность факторов риска сердечно-сосудистых заболеваний у работников железнодорожного транспорта с артериальной гипертонией. Забайкальский медицинский вестник 2015;(2):113–8. [Shtarik S.Yu. Prevalence of cardiovascular diseases’ risks factors at railroad employees with arterial hypertension. Zabaykal’skiy meditsinskiy vestnik = Zabaikalsky Medical Bulletin 2015;(2):113–8. (In Russ.)].

22. Абдурасулов К.Д., Дурбелова Б.Н. Липидный спектр крови среди неорганизованной популяции г. Ханты-Мансийска. Вестник КГМА им. И.К. Ахунбаева 2015;1(1):27–31. [Аbdurasulov K.D., Dubelovа B.N. Lipid blood spectrum among the non-organized population of the city of Khanty-Mansiisk. Vestnik KGMA im. I.K. Akhunbaeva = Herald of I.K. Ahunbaev KSМА 2015;1(1):27–31. (In Russ.)].

23. Абусуев С.А., Асадулаева М.Н. Распространенность компонентов метаболического синдрома в различных этнических группах населения Дагестана. Сборник тезисов VII Всероссийского диабетологического конгресса. М., 2015. C. 222. [Аbusuev S.А., Аsadulaevа М.N. Prevalence of metabolic syndrome components in different ethnic groups of Dagestan population. Volume of proceedings of the VII All-Russian diabetological congress. Мoscow, 2015. P. 222. (In Russ.)].

24. Blumenthal R.S., Foody J.A., Wong N.D. et al. Preventive cardiology: A Companion to Braunwald’s Heart Disease: 1nd edn. Saunders, 2011.

25. Пуска П., Вартиайнен Э., Паатикайнен Т. и др. Проект «Северная Карелия»: от Северной Карелии до проекта национального масштаба. Хельсинки: Издательство Университета Хельсинки, 2011. [Puskа P., Vartiaynen E., Paatikaynen Т. et al. “North Karelia” project: from North Karelia to the national scale project. Helsinki: Helsinki University Edition, 2011. (In Russ.)].

26. Frank S., Kostner G. Lipoproteins – role in health and diseases. InTech, 2012.

27. Hwang Y.C., Park C.Y., Ahn H.Y., Cho N.H. Prediction of future development of cardiovascular disease with an equation to estimate apolipoprotein B: А communitybased cohort study. Medicine (Baltimore) 2016;95(24):e3644.

28. Mooradian A.D. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5(3):150–9.

29. Tsimihodimos V., Mitrogianni Z., Elisaf M. Dyslipidemia Associated with Chronic Kidney Disease. Open Cardiovasc Med J 2011;5:41–8.

30. Kes P., Bašić-Kes V., Furic-Cunko V. et al. Dyslipidemia and stroke in patients with chronic kidney disease. Acta Med Croatica 2014;68(2):141–9.

31. Angeli V., Llodrá J., Rong J.X. et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004;21(4):561–74.

32. Contois J.H., McConnell J.P., Sethi A.A. et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55(3):407–19.

33. Walldius G., Jungner I., Holme I. et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358(9298):2026–33.

34. Holme I., Aastveit A.H., Jungner I. et al. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2008;264(1):30–8.

35. Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937–52.

36. Sandhu P.K., Musaad S.M., Remaley A.T. et al. Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review. J Appl Lab Med 2016;1(2):214–29.

37. Yeboah J., McClelland R.L., Polonsky T.S. et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012;308(8):788–95.

38. Tada H., Melander O., Louie J.Z. et al. Risk prediction by genetic risk scores for coronary heart disease is independent of selfreported family history. Eur Heart J 2016;37(6):561–7.